Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

20100125.TNBC

— · E

63fa2e68-7eb9-5cf6-ab12-2616c1cb845c

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
E
subtype
E

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.700
  • MYC_TARGETS_V1+0.630
  • E2F_TARGETS+0.580
  • ALLOGRAFT_REJECTION+0.530
  • G2M_CHECKPOINT+0.530
  • INTERFERON_GAMMA_RESPONSE+0.470
  • INTERFERON_ALPHA_RESPONSE+0.460
  • INFLAMMATORY_RESPONSE+0.440
  • IL6_JAK_STAT3_SIGNALING+0.370
  • NOTCH_SIGNALING+0.280

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
  • TGF_BETA_SIGNALING-0.380
  • ESTROGEN_RESPONSE_EARLY-0.340
  • UV_RESPONSE_DN-0.330
  • MYOGENESIS-0.310
  • CHOLESTEROL_HOMEOSTASIS-0.270
  • BILE_ACID_METABOLISM-0.250
  • PANCREAS_BETA_CELLS-0.250
  • ESTROGEN_RESPONSE_LATE-0.240
  • PROTEIN_SECRETION-0.240

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-E2-A1II-01A-11R-A144-07
breast-umap@18
—E0.922
2TCGA-B6-A0IJ-01A-11R-A034-07
breast-umap@18
—E0.895
3MBCproject_0095_T3_RNA
breast-umap@18
—E0.892
4TCGA-BH-A1FC-01A-11R-A13Q-07
breast-umap@18
—E0.890
5TCGA-AC-A6IW-01A-12R-A33J-07
breast-umap@18
—E0.886
6TCGA-AR-A1AI-01A-11R-A12P-07
breast-umap@18
—E0.883
7c63f3f74-14fa-4a9e-9925-30b0f5da7dd9
colon-landscapes@1
——0.877
820060324.TNBC
breast-umap@18
—D0.876
9TCGA-E2-A14N-01A-31R-A137-07
breast-umap@18
—E0.870
1020130015.TNBC
breast-umap@18
—E0.864

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 24 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.700Idelalisib— uncovered
MYC_TARGETS_V10.630Inavolisib— uncovered
E2F_TARGETS0.580Inavolisib— uncovered
ALLOGRAFT_REJECTION0.530Idelalisib— uncovered
G2M_CHECKPOINT0.530Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.470Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.460Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.440Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.370Inavolisib— uncovered
NOTCH_SIGNALING0.280Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.280Inavolisib— uncovered
MTORC1_SIGNALING0.260Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.250Remibrutinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.230Inavolisib— uncovered
COMPLEMENT0.220Inavolisib— uncovered
DNA_REPAIR0.180Idelalisib— uncovered
MITOTIC_SPINDLE0.180Inavolisib— uncovered
IL2_STAT5_SIGNALING0.160Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.160Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.150Idelalisib— uncovered